Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset - HMS LINCS Database

Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Antibodies

<
<<
Previous
Page 1 of 4
Next
>>
>
1 to 25 of 90 records
per page:

Small Molecule	Antibody	Perturbagen Target	Perturbagen Class	GR50 lower quartile	GR50 median	GR50 upper quartile	GRmax lower quartile	GRmax median	GRmax upper quartile	GRinf lower quartile	GRinf median	GRinf upper quartile	Hill Coefficient lower quartile	Hill Coefficient median	Hill Coefficient upper quartile	GR_AOC lower quartile	GR_AOC median	GR_AOC upper quartile	GEC50 lower quartile	GEC50 median	GEC50 upper quartile
Nilotinib		ABL	nRTK	100.0000	100.0000	100.0000	0.7849	0.9109	1.0055	0.7841	0.9109	1.0055	0.0000	0.0000	0.7234	0.0029	0.0487	0.0775	73.6076	100.0000	100.0000
AG1024		IGF1R	RTK	14.2327	62.8199	100.0000	0.3069	0.5828	0.8614	-0.0340	0.2904	0.6353	0.3280	1.4424	3.0172	0.0186	0.0785	0.1208	8.3409	30.1991	100.0000
Sorafenib		PDGFR/VEGFR/KIT/FLT3	RTK	36.5873	68.4588	100.0000	-0.7737	-0.2023	0.2203	-0.7439	-0.3900	0.2345	0.6570	1.9429	3.4993	0.1339	0.2188	0.2978	54.8881	71.4700	100.0000
Dactolisib		PI3K	PI3K	0.1885	0.5181	100.0000	0.2549	0.5042	0.6208	0.2262	0.4314	0.5885	0.0000	2.2633	4.9147	0.2133	0.2744	0.3494	0.1148	0.3521	100.0000
TPCA-1		IKK	NFKB	4.9121	23.5816	100.0000	0.0988	0.4346	0.6277	-0.1071	0.3912	0.5674	0.5796	1.2158	2.2892	0.0966	0.1616	0.2244	2.5700	5.7466	43.2238
AS-252424		PI3K	PI3K	19.5544	36.2256	100.0000	0.2865	0.4240	0.5918	-0.9991	0.2157	0.5619	0.3148	0.6846	2.7243	0.0770	0.1059	0.1601	6.6689	89.5846	100.0000
TCS PIM-1 1		Pim kinase	PIM	90.9415	100.0000	100.0000	0.4852	0.6734	0.7827	0.3505	0.5918	0.7255	0.0000	1.5057	4.5238	0.0404	0.0756	0.1063	26.3980	73.0639	100.0000
Sirolimus		MTOR	MTOR	0.0785	2.7199	100.0000	-0.0907	0.1172	0.3521	-0.3854	0.0690	0.4042	0.2746	0.5743	1.0909	0.2471	0.4095	0.5054	0.0261	0.5698	12.7823
Erlotinib		EGFR	ErbB	6.4716	35.2468	100.0000	0.0317	0.4006	0.6354	-0.8374	-0.1704	0.3788	0.3155	0.7139	1.8126	0.0351	0.1228	0.2396	13.2839	41.2968	100.0000
Vorinostat		HDAC	HDAC	72.1503	100.0000	100.0000	-0.8970	-0.8099	-0.5591	-0.9320	-0.8403	-0.5970	1.0273	1.3201	1.6251	0.4794	0.5820	0.7389	100.0000	100.0000	100.0000
AG1478		EGFR	ErbB	8.7673	51.6075	100.0000	-0.0710	0.2684	0.6341	-0.3109	-0.0273	0.4206	0.8939	1.7205	2.6373	0.0902	0.1531	0.2936	3.7212	36.6666	94.4655
PS-1145		IKK	NFKB	100.0000	100.0000	100.0000	0.8452	0.9304	0.9718	0.8353	0.9304	0.9695	0.0000	0.0000	0.8067	-0.0033	0.0200	0.0533	100.0000	100.0000	100.0000
Dichloroacetate		PDK	PDK	100.0000	100.0000	100.0000	0.8082	0.8801	0.9216	0.7946	0.8670	0.9296	0.0000	0.0000	0.2064	0.0234	0.0440	0.0744	58.3872	100.0000	100.0000
SB-3CT		MMP2/9	MMP	69.9094	100.0000	100.0000	0.4441	0.6795	0.8316	-0.1049	0.6210	0.7846	0.0670	0.6905	2.4960	0.0290	0.0754	0.1306	27.8608	93.1362	100.0000
JNK-IN-5A		JNK	JNK	1.8491	14.2132	100.0000	-0.1818	0.1302	0.4971	-0.4099	0.0435	0.4984	0.0000	3.1821	4.9999	0.0989	0.2367	0.3549	1.4898	12.5032	100.0000
Lapatinib		EGFR/HER2	ErbB	31.2806	100.0000	100.0000	0.4954	0.7950	0.9113	0.2428	0.7519	0.9066	0.0000	0.2457	1.3492	0.0247	0.0703	0.1302	1.5972	63.5403	100.0000
	Cetuximab	EGFR	ErbB	100.0000	100.0000	100.0000	0.7284	0.8755	0.9754	0.5964	0.8555	0.9754	0.0000	0.0000	0.7916	-0.0099	0.0234	0.0674	3.7461	100.0000	100.0000
FR180204		ERK1/2	MAPK	56.2203	100.0000	100.0000	0.4862	0.6317	0.8238	-0.1433	0.2500	0.7055	0.0180	0.6403	1.9539	0.0470	0.0722	0.1058	65.9938	100.0000	100.0000
FTase Inhibitor I		Ftase	MAPK	100.0000	100.0000	100.0000	0.7715	0.8851	0.9752	0.7468	0.8851	0.9752	0.0000	0.0000	0.0000	0.0099	0.0556	0.0941	100.0000	100.0000	100.0000
PD 98059		MEK	MAPK	100.0000	100.0000	100.0000	0.5235	0.6650	0.8191	-0.1517	0.5395	0.8149	0.0000	0.2473	0.7779	0.0463	0.0842	0.1501	32.4005	100.0000	100.0000
PD184352		MEK	MAPK	31.0822	100.0000	100.0000	0.4258	0.7584	0.9084	-0.2272	0.7139	0.9084	0.0000	0.0524	0.4766	0.0368	0.0888	0.1432	63.7076	100.0000	100.0000
Selumetinib		MEK	MAPK	3.4703	100.0000	100.0000	0.2888	0.6993	0.8618	0.1384	0.6524	0.8687	0.0000	0.4990	0.9393	0.0510	0.1233	0.3040	0.3246	2.6951	100.0000
Trametinib		MEK	MAPK	0.1119	60.3200	100.0000	0.2676	0.5669	0.7582	0.2515	0.4183	0.5896	0.4854	1.1532	1.7735	0.0718	0.1864	0.3779	0.0100	0.4479	33.6419
Valproic acid		HDAC	HDAC	100.0000	100.0000	100.0000	-0.8969	-0.6820	-0.4277	-0.5381	-0.3207	-0.1180	1.1443	1.2884	1.4704	0.1935	0.2464	0.2891	100.0000	100.0000	100.0000
ZM-447439		AURK	AURK	3.5193	19.1991	100.0000	-0.0403	0.4141	0.5578	-0.1176	0.3301	0.5652	0.5578	1.0337	2.9596	0.1428	0.2012	0.3024	0.6732	2.5837	16.4745

<
<<
Previous
Page 1 of 4
Next
>>
>
1 to 25 of 90 records
per page:

HMS LINCS Project

Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen. - Dataset (ID:20270)